Table 2.

Antifungal drugs discovered in the last 5 years.

drug	therapeutic target	Effect of administration	Spectrum of activity
Sirt2 deacetylase inhibitors (AGK2, AK-1, or AK-7) (25)	Inhibition of the deacetylase SIRT2 enhances α-tubulin acetylation and thus enhances antifungal immune responses at the cellular level.	administration of the Sirt2 deacetylase inhibitors AGK2, AK-1 and AK-7 protected mice against both systemic and central nervous system C. albicans infections.	C. albicans
Nanocarrier-delivered Rac1 mRNA(mRac1@LNP) (32)	enhancing antifungal immunity by boosting Rac1 activity through the introduction of nanocarrier-delivered Rac1 single-stranded mRNA. mRac1@LNP transfection significantly increased ROS production after curdlan, mannan or HKCA stimulation.	injection of mRac1@LNPs significantly attenuated the severity of candidemia.	C. albicans
JNK1 inhibitor(SP600125, JNK-IN-8) (33)	Increased CD23 expression is induced when jnk1 is inhibited, which promotes antifungal immunity.	JNK inhibitors exerted potent anti-fungal therapeutic effects in C. albicans-infected mouse and human cells.	C. albicans